Get prepared with the key expectations. ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared ...

In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a price target of $8.00. The company’s shares closed ...